Document is current
Any future updates will be listed below
-
Authors
Rea, Delphine https://orcid.org/0000-0001-5379-7461
Kyrcz-Krzemien, Slawomira
Sportoletti, Paolo
Mayer, Jiří https://orcid.org/0000-0003-0567-9887
Illes, Arpad
Angona Figueras, Anna
Kiani, Alexander https://orcid.org/0000-0002-2494-4087
Charbonnier, Aude https://orcid.org/0000-0003-0986-9530
Marinakis, Theodoros
Stenke, Leif
Steegmann, Juan Luis https://orcid.org/0000-0002-7799-5355
Saglio, Giuseppe https://orcid.org/0000-0002-1046-3514
Hellmann, Andrzej
Niederwieser, Dietger https://orcid.org/0000-0002-4737-1103
Schuld, Peter
Rosti, Gianantonio
-
Funding
Funding for this research was provided by:
Novartis Pharma AG
- License Information
-
More Information
Article History
Received: 10 June 2025
Revised: 6 October 2025
Accepted: 12 December 2025
First Online: 19 January 2026
Competing interests
: DR is on the advisory board for Novartis, Enliven, TERNS, and Ascentage Pharma and is a consultant for TERNS and Novartis. JM received research support from Novartis. AI received consulting fees from Janssen, Swixx, Takeda, Astrazeneca, Astellas, Eli Lilly, Roche; honoraria from Astrazeneca, Astellas, Eli Lilly, Roche, Sobi; travel/meeting support from AbbVie, Sobi; Is on data monitoring/ advisory board at Sobi, Bristol-Myers Squibb, Johnson & Johnson, Novartis, AbbVie, Astellas, Roche, Astrazeneca. AK declared Novartis honoraria membership on an entity’s board of directors or advisory committees, research funding, and speakers bureau. AC has served on advisory boards and has acted as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pfizer. PS declared that he is an employee of Novartis. LS received consulting fees from Xspray Pharma Sweden. The remaining authors declare no competing financial interests.
